$ACON

Neal David K purchased $18K of ACON

Neal David K purchased 7,500 shares of Aclarion, Inc. (ACON) at $2.40 on 2026-08-13.

Original reporting
SEC EDGAR · Neal David K
Published Aug 17, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACON
Bullish
low confidence
Mentioned
$ACON
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACONBullishLow
01

Why it matters

The newest disclosed fact is an open-market purchase by a director: 7,500 shares at $2.40 for $18,000 total, with holdings after the trade of 30,002 shares.

02

Market read

Traders may view the insider buy as mildly positive sentiment, but there is no accompanying guidance, contract, or operational update.

03

What to watch

No 10b5-1 plan is cited, but the article provides no context on prior trading patterns, motivations, or whether the director’s holdings are already large.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction disclosure for Aclarion, Inc. (ACON).

Company-level read

Ticker impact

$ACONBullishLow confidence
Context

Aclarion director Neal David K filed a Form 4 open-market purchase of 7,500 shares at $2.40 on 2026-08-13.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider purchases can be informative, but this transaction size and lack of accompanying company-specific news reduce tradable impact.

Market effects

No sector-wide implications disclosed; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or driven by personal liquidity planning, and this filing does not indicate a change in company fundamentals.

Key entities

  • Aclarion, Inc.

    US-listed company subject of the Form 4 insider transaction disclosure.

  • Neal David K

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACONMed

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

$ACONMedAI 8/10

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.